Dashboard
Manage Tickers

TAK TAKEDA PHARMACEUTICAL CO LTD

NYSE takeda.com


$ 13.43 $ 0.01 (0.07 %)    

Friday, 31-Oct-2025 10:19:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 631.91 $ -2.08 (-0.33 %)
DIA $ 475.55 $ -0.34 (-0.07 %)
SPY $ 683.27 $ -1.73 (-0.25 %)
TLT $ 90.51 $ -0.05 (-0.06 %)
GLD $ 370.18 $ -0.27 (-0.07 %)
$ 13.23
$ 13.45
$ 13.43 x 2,691
$ 13.43 x 775
$ 13.39 - $ 13.48
$ 12.80 - $ 15.69
5,215,763
na
22.45B
$ 0.31
$ 31.19
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

takeda-lowers-2025-outlook-after-weak-q2-and-pipeline-impairment-charges
Takeda Lowers 2025 Outlook After Weak Q2 A...
10/30/2025 13:13:01

Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenu...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

takeda-pharmaceutical-co-lowers-fy2025-adj-eps-guidance-from-336-to-325-lowers-fy2025-sales-guidance-from-31339b-to-30524b
Takeda Pharmaceutical Co Lowers FY2025 Adj...
10/30/2025 10:45:13

Takeda Pharmaceutical Co (NYSE:TAK) lowers FY2025 Adj EPS guidance from $3.36 to $3.25. Lowers FY2025 sales outlook from $31.33...

takeda-pharmaceutical-q2-adj-eps-043-misses-044-estimate-sales-7520b-miss-8080b-estimate
Takeda Pharmaceutical Q2 Adj. EPS $0.43 Mi...
10/30/2025 07:17:51

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of ...

takedas-hyhub-hyhub-duo--devices-now-available-in-us-for-patients-17-years-older
Takeda's HyHub, HyHub Duo Devices Now Ava...
10/27/2025 12:43:48

Takeda ((

Core News & Articles
Reported Earlier, Takeda And Innovent Biol...
10/22/2025 07:41:09

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and a...

takeda-taps-nabla-bios-generative-ai-platform-for-antibody-design-in-1-billion-pact
Takeda Taps Nabla Bio's Generative AI Plat...
10/14/2025 18:41:04

Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential su...

johnson--johnson-in-talks-to-acquire-protagonist-therapeutics-report
Johnson & Johnson In Talks To Acquire Prot...
10/10/2025 17:06:05

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...

whats-going-on-with-nano-cap-galecto-stock-on-tuesday
What's Going On With Nano-Cap Galecto Stoc...
10/07/2025 17:05:49

Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and cli...

reported-earlier-takeda-expands-global-csr-program-to-537m-beneficiaries-with-jpy-46b-commitment-across-94-countries
Reported Earlier, Takeda Expands Global CS...
09/24/2025 06:38:22

takeda-vela-to-transport-products-between-europe-us-using-sailing-cargo-trimaran
Takeda, VELA To Transport Products Between...
09/16/2025 12:16:50

takeda-reports-results-from-firstlight-and-radiantlight-studies-showing-oveporexton-improves-wakefulness-cataplexy-severity-and-quality-of-life
Takeda Reports Results From FirstLight And...
09/08/2025 07:25:42

– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025–...

on-friday-fda-approved-takedas-supplemental-application-for-vonvendi-expanding-the-indication-to-include-routine-prophylaxis-to-reduce-the-frequency-of-bleeding-episodes-in-adults-with-von-willebrand-disease
On Friday, FDA Approved Takeda's Supplemen...
09/07/2025 16:27:32

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (...

Core News & Articles
Novavax Receives Milestone Payment From Ta...
09/04/2025 12:10:22

takeda-canada-announces-fruzaqlatm-will-now-be-reimbursed-by-ramq-in-quebec
Takeda Canada Announces FRUZAQLATM Will No...
08/28/2025 13:31:18

whats-going-on-with-takeda-stock-on-friday
What's Going On With Takeda Stock On Friday?
08/22/2025 15:21:49

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to ...

ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder
Ionis Pharma Wins FDA Nod For First RNA-Ta...
08/21/2025 18:24:53

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...

takeda-pharma-maintains-outlook-even-as-vyvanse-generics-hit-sales
Takeda Pharma Maintains Outlook Even As Vy...
07/30/2025 20:04:11

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and ...

Core News & Articles
Earnings Scheduled For July 30, 2025
07/30/2025 08:32:48

takeda-reaffirms-fy2025-guidance-core-revenue-of-4530b-and-core-operating-profit-broadly-flat-at-1140b-core-eps-of-485
Takeda Reaffirms FY2025 Guidance, Core Rev...
07/30/2025 06:45:36

FY2025 Outlook (unchanged from May 2025)(Billion yen, except percentages and per share amounts)ItemFY2025 FORECASTFY2025 MANAGE...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION